{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T05:03:26Z","timestamp":1737435806329,"version":"3.33.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1136\/ard.2007.086330","type":"journal-article","created":{"date-parts":[[2008,4,14]],"date-time":"2008-04-14T15:59:42Z","timestamp":1208188782000},"page":"577-579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Do we need treatment with tumour necrosis factor blockers for giant cell arteritis?"],"prefix":"10.1016","volume":"67","author":[{"given":"Carlo","family":"Salvarani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00f2","family":"Pipitone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Boiardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gene G","family":"Hunder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2007.086330_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMra011913","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"347","author":"Salvarani","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.086330_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/BOR.0b013e3282f31769","article-title":"Improving therapeutic options for patients with giant cell arteritis","volume":"20","author":"Pipitone","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard.2007.086330_bib3","first-page":"1484","article-title":"A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year follow-up study of 164 patients","volume":"27","author":"Chevalet","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.086330_bib4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000070631","article-title":"Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies","volume":"217","author":"Hayreh","year":"2003","journal-title":"Ophthalmologica"},{"key":"10.1136\/ard.2007.086330_bib5","first-page":"205","article-title":"Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy","volume":"5","author":"Salvarani","year":"1987","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2007.086330_bib6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.0954-6820.1986.tb02796.x","article-title":"Long-term corticosteroid reatment in giant cell arteritis","volume":"220","author":"Andersson","year":"1986","journal-title":"Acta Med Scand"},{"key":"10.1136\/ard.2007.086330_bib7","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arterits: duration and adverse outcomes","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.086330_bib8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2007.086330_bib9","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.086330_bib10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/art.21075","article-title":"Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis","volume":"53","author":"Salvarani","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.086330_bib11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0161-6420(93)31608-8","article-title":"Visual prognosis in giant cell arteritis","volume":"100","author":"Aiello","year":"1993","journal-title":"Ophthalmology"},{"key":"10.1136\/ard.2007.086330_bib12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00005792-200009000-00001","article-title":"Visual manifestations of giant cell arteritis: trends and clinical spectrum in 161 patients","volume":"79","author":"Gonzalez-Gay","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"10.1136\/ard.2007.086330_bib13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.md.0000145369.25558.b5","article-title":"Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis","volume":"83","author":"Gonzalez-Gay","year":"2004","journal-title":"Medicine"},{"key":"10.1136\/ard.2007.086330_bib14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/01.md.0000119761.27564.c9","article-title":"Risk factors for cranial ischemic complications in giant cell arteritis","volume":"83","author":"Nesher","year":"2004","journal-title":"Medicine"},{"key":"10.1136\/ard.2007.086330_bib15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.bor.0000197996.04709.4e","article-title":"Large-vessel involvement in giant cell arteritis","volume":"18","author":"Bongartz","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard.2007.086330_bib16","first-page":"495","article-title":"A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA)","volume":"19","author":"Spiera","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2007.086330_bib17","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive methotrexate for treatment of giant cell arteritis. An individual patient data meta-analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.086330_bib18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.45.2.136","article-title":"Azathioprine in giant cell arteritis\/polymyalgia rheumatica: a double-blind study","volume":"45","author":"De Silva","year":"1986","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.086330_bib19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2007.086330_bib20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-146-9-200705010-00005","article-title":"Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia reumatica. A randomized trial","volume":"146","author":"Salvarani","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2007.086330_bib21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Martinez-Taboada","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.086330_bib22","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/rheumatology\/keh058","article-title":"Tissue production of pro-inflammatory cytokines (IL-1\u03b2, TNF\u03b1 and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis","volume":"43","author":"Hernandez-Rodriguez","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2007.086330_bib23","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-148-2-200801150-00018","article-title":"A potential role for TNF-blocking agents in polymyalgia rheumatica and giant cell arteritis [rapid response letter]","author":"Salvarani","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2007.086330_bib24","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1002\/1529-0131(200112)44:12<2933::AID-ART482>3.0.CO;2-Y","article-title":"Treatment of longstanding active giant cell arteritis with infliximab: report of four cases","volume":"44","author":"Cantini","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.086330_bib25","first-page":"760","article-title":"Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study","volume":"30","author":"Salvarani","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.086330_bib26","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/art.23095","article-title":"Treatment of refractory polymyalgia reumatica with etanercept: an open pilot study","volume":"57","author":"Catanoso","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.086330_bib27","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/art.1780360913","article-title":"Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis","volume":"36","author":"Roche","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.086330_bib28","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/1529-0131(200005)43:5<1041::AID-ANR12>3.0.CO;2-7","article-title":"Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity","volume":"43","author":"Weyand","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.086330_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.20901","article-title":"Acute phase response reactants and the risk of developing relapse\/recurrence in polymyalgia rheumatica: a prospective follow up study","volume":"53","author":"Salvarani","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1136\/ard.2007.086330_bib30","first-page":"S21","article-title":"Interleukin-6 inhibition. Tolerability profile and clinical implications","volume":"65","author":"Strand","year":"2007","journal-title":"Bull NYU Hosp JT Dis"},{"key":"10.1136\/ard.2007.086330_bib31","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/ard.2005.036533","article-title":"Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis","volume":"64","author":"Bhatia","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.086330_bib32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1517\/14712598.8.1.115","article-title":"Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis","volume":"8","author":"Chitale","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"10.1136\/ard.2007.086330_bib33","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/art.22163","article-title":"Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial","volume":"54","author":"Mazlumzadeh","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.086330_bib34","doi-asserted-by":"crossref","first-page":"613","DOI":"10.7326\/0003-4819-82-5-613","article-title":"Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study","volume":"82","author":"Hunder","year":"1975","journal-title":"Ann.Intern.Med"},{"key":"10.1136\/ard.2007.086330_bib35","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/ard.48.8.658","article-title":"Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months","volume":"48","author":"Kyle","year":"1989","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.086330_bib36","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/ard.47.9.733","article-title":"Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients)","volume":"47","author":"Delecoeuillerie","year":"1988","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.086330_bib37","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/ard.2003.018556","article-title":"How to prevent steroid induced osteoporosis","volume":"64","author":"Sambrook","year":"2005","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724217945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724217945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2007.086330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T05:46:54Z","timestamp":1737352014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724217945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0003496724217945"],"URL":"https:\/\/doi.org\/10.1136\/ard.2007.086330","relation":{},"ISSN":["0003-4967"],"issn-type":[{"type":"print","value":"0003-4967"}],"subject":[],"published":{"date-parts":[[2008,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do we need treatment with tumour necrosis factor blockers for giant cell arteritis?","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2007.086330","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1136\/ard.2007.082115","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 2008 Published by Elsevier Inc. Publishing Group and European League Against Rheumatism. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}